SAN DIEGO - April 18, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (
OTCBB: AEMD),
disclosed that a poster presentation entitled: "Extracorporeal Exosome
Removal: A Therapeutic Strategy to Address an Evolutionary Survival
Mechanism Shared by Cancer and Infectious Viral Pathogens," is being
presented today at the International Society of Extracellular Vesicles
(ISEV) 2013 conference being held in Boston, MA. Dr. Annette Marleau,
Director of Tumor Immunology at Aethlon Medical will give the
presentation. Information related to ISEV 2013 can be accessed online
at:
www.isevmeeting.org
The Aethlon presentation discusses the specificity of the Aethlon
Hemopurifier® to address evolved glycopathogen targets that are
instrumental in cancer and infectious disease progression. Significant
points addressed in the presentation include emerging knowledge of
exosome secretion, which is a notable feature of malignancy owing to the
diverse roles of these particles in tumor-mediated immune suppression,
angiogenesis, metastasis, and resistance to therapeutic agents. As
cancer-secreted exosomes remain a critical target not addressed by drug
therapies, the Company is expanding the potential utility of the
Hemopurifier® to include cancer. In this role, the Hemopurifier®
provides an adjuvant strategy to improve current and emerging cancer
treatment outcomes without adding drug toxicity. To date, pre-clinical
Hemopurifier® studies have validated the capture of exosomes underlying
breast cancer, metastatic melanoma, ovarian cancer, lymphoma, and
colorectal cancer.
The Aethlon Hemopurifier® consists of the lectin Galanthus nivalis
agglutinin (GNA) immobilized in the outer-capillary space of a plasma
membrane device that is compatible for use with standard CRRT and
dialysis units. GNA-based capture is mediated by unique high mannose
signatures abundant on the surface of cancer-secreted exosomes as well
as glycoproteins that reside on the outer membrane of infectious viral
pathogens.
In human studies of treatment naive HIV and Hepatitis-C (HCV)
infected individuals, Hemopurifier® therapy demonstrated average viral
load reductions of greater than 50% during single four-hour treatment
applications. A three-treatment Hemopurifier® protocol combined with
interferon-based standard-of-care resulted in undetectable HCV in as
little as seven days in hard-to-treat genotype-1 patients. In this same
clinical program, post-treatment elution studies documented the capture
of up to 300 billion HCV copies by the Hemopurifier® during a single
six-hour treatment. A human feasibility study to initiate HCV human
studies in the United States is pending IDE approval by the U.S. Food
and Drug Administration (FDA).
Based on human treatment experience and exosome capture
validations, the Company has identified candidate research centers to
conduct a Hemopurifier® therapy study in cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address
unmet medical needs in cancer, infectious disease, and other
life-threatening conditions. Our Aethlon ADAPT™ System is a
revenue-stage technology platform that provides the basis for a new
class of devices the rapid, yet selective removal of disease promoting
particles from the entire circulatory system. At present, The Aethlon
ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address
infectious disease and cancer, and a medical device being developed
under a 5-year contract with Defense Advanced Research Projects Agency
(DARPA) to reduce the incidence of sepsis in combat-injured soldiers.
For more information, please visit
www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that
selectively targets the rapid clearance of infectious viral pathogens
and immunosuppressive proteins from the entire circulatory system. In
the treatment of Hepatitis C virus (HCV), human studies have
demonstrated that Hemopurifier® therapy may improve immediate, rapid and
sustained virologic response rates when administered in the first few
days of standard-of-care drug therapy. In addition to accelerating viral
load depletion, post-treatment analysis of the Hemopurifier® has
documented the capture of up to 300 billion HCV copies of HCV during a
single six-hour treatment. Access to Hemopurifier® therapy is available
on a compassionate-use basis through the Medanta Medicity Institute
(Medicity), a leading center for medical tourism in India. The Medicity
is offering treatment access to infected individuals who previously
failed or subsequently relapsed standard-of-care drug regimens. The
Hemopurifier® is also being offered as a salvage therapy to infected
individuals who suffer a viral breakthrough during standard-of-care
therapy. U.S. studies of the Hemopurifier® are currently pending
approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of
infectious viral pathogens, the Hemopurifier® has been discovered to
capture tumor-derived exosomes underlying several forms of cancer.
Tumor-derived exosomes have recently emerged to be a vital therapeutic
target in cancer care. These microvesicular particles suppress the
immune response in cancer patients through apoptosis of immune cells and
their quantity in circulation correlates directly with disease
progression. Beyond possessing immunosuppressive properties,
tumor-derived exosomes facilitate tumor growth, metastasis, and the
development of drug resistance. By addressing this unmet medical need,
the Hemopurifier® is positioned as an adjunct to improve established
cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Aethlon
Medical, Inc. to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, that the company can successfully protect its intellectual
property, that removal of exosomes from the human body will impact or
lead to successful treatment of cancer, or that exosomes are the cause
of tumor growth and progression, that the FDA will not approve the
initiation of the Company's clinical programs or provide market
clearance of the company's products, future human studies whether
revenue or non-revenue generating of the Aethlon ADAPT™ system or the
Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy, the Company's ability to raise
capital when needed, the Company's ability to complete the development
of its planned products, the Company's ability to manufacture its
products either internally or through outside companies and provide its
services, the impact of government regulations, patent protection on the
Company's proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and
other risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and other
risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of
new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news
and research. Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent
research. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. This site is
currently compensated by featured companies, news submissions and online
advertising. If you have any questions regarding information in this
press release please contact the company listed in the press release.
Aethlon Medical, Inc. is currently an annual news release client at
Investorideas.com and compensates Investorideas.com $2425 quarterly to
publish and distribute news with Investorideas and its syndication
partners
Investorideas.com Disclaimer:
http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure:
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
More info on AEMD: